PHARMACON
ActiveSummary
PHARMACON has been active since 1996 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €275,949 and a net result of -€33,237. Equity is shrinking by about 2.5% per year across the filed financial years. Its solvency ranks better than 57% of 38,739 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
28-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
30-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 30 days late
2023
31-12
Financial
Weakest financial yearnet -€47,079
Net result drops to -€47,079, the lowest in the series; recovery starts the following year.
16-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 16 days late
2022
29-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 29 days late
2021
31-12
Financial
Back to profitnet €52,551
Net result €52,551 after 2 loss-making years.
16-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 16 days late
2020
13-08
NBB filing
Annual accounts filed
financial year 2019 · micro format · 13 days late
2019
12-08
NBB filing
Annual accounts filed
financial year 2018 · micro format · 12 days late
2018
07-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 7 days late
2017
22-08
NBB filing
Annual accounts filed
financial year 2016 · micro format · 22 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 29 annual accounts filed, the latest 10 are here; all 29 are at the National Bank.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.